Price range: $80.00 through $100.00
| Quantity | Discount (%) | Price |
|---|---|---|
| 1 | — | $80.00 |
| 3 | 12.5 % | $70.00 |
| 6 | 18.75 % | $65.00 |
| 12+ | 25 % | $60.00 |
Free bacteriostatic water with every order.
Use our Research Peptide Storage Guide — Laboratory Use Only — to ensure proper handling and stability for controlled experimental applications. Not for human consumption, therapeutic, or diagnostic use.
Chemical Formula: Sequence-dependent (GLP-1 analogue–based structure)
Molecular Weight: ~3,000–4,500 g/mol (dependent on sequence modifications)
CAS Number: Research designation / Assigned upon structural registration
Structure: Engineered GLP-1–derived peptide analogue designed for enhanced receptor activation and metabolic stability
Form: Lyophilized peptide powder
Solubility: Soluble in sterile water or buffered aqueous solution
Stability: Stable when stored frozen; limited stability after reconstitution
Half-Life: Extended compared to native GLP-1 through structural modification
Storage: Store refrigerated at 36–46°F (2–8°C); protect from light and moisture
Binds to GLP-1 receptors in pancreatic, neural, and gastrointestinal tissues to regulate metabolic signaling
Enhances insulin secretion in response to elevated blood glucose levels
Reduces inappropriate glucagon release to support improved glycemic control
Slows gastric emptying and influences central appetite pathways to reduce caloric intake
Studied for improved glycemic control and enhanced insulin sensitivity in metabolic models
Investigated for reductions in body fat and improvements in weight management research
Explored for decreased hunger signaling and improved satiety response
Evaluated for positive effects on lipid metabolism and cardiometabolic markers
Preclinical and clinical studies demonstrate:
Reduced fasting and postprandial glucose levels
Improved HbA1c markers in diabetic models
Enhanced glucose-dependent insulin response
Research shows:
Reduced caloric intake via appetite suppression
Decreased body weight in obesity models
Improved adiposity and metabolic efficiency
Evidence suggests:
Improved endothelial function markers
Reduced cardiometabolic risk indicators
Support for blood pressure modulation in metabolic disease
Studies indicate:
Reduced systemic inflammatory markers
Improved metabolic stress signaling
Enhanced mitochondrial metabolic activity
Effects appear dose-dependent and typically resolve after the peptide’s active pharmacological period.
Temporary nausea, reduced appetite beyond intended levels, mild gastrointestinal discomfort
Transient changes in glucose dynamics during dose escalation
Safety profile is based primarily on preclinical and early clinical research.
Dosing is generally individualized and titrated based on response and tolerability
Independent laboratory testing confirms purity and composition
Purity
Batch
Date
